Blood DNA Methylation Predicts Long-Term Risk of Dementia in Prospective Cohorts

Area of Science:

• Epigenetics
• Neuroscience
• Gerontology

Background:

• Blood-based DNA methylation may offer early insights into dementia risk.
• Identifying pre-symptomatic biomarkers is crucial for dementia prevention strategies.

Purpose of the Study:

• To investigate blood DNA methylation patterns associated with long-term dementia risk.
• To identify and validate novel epigenetic biomarkers for incident all-cause dementia.

Main Methods:

• Conducted an epigenome-wide association study (EWAS) in 5,999 cognitively healthy women.
• Tested baseline blood DNA methylation for association with dementia onset over 25 years.
• Replicated findings in four independent cohorts and examined brain methylation data.

Main Results:

• One CpG site, cg05917797, showed a significant association with dementia risk (higher methylation, lower risk).
• This association remained robust after adjusting for APOE ε4, plasma p-tau217, and epigenetic age.
• Replication in meta-analyses confirmed cg05917797 as a reproducible marker, also linked to lower Braak stage in brain tissue.

Conclusions:

• cg05917797 is a reproducible blood-based epigenetic marker for long-term dementia risk.
• This finding supports the potential of DNA methylation for early dementia risk assessment.
• Further research identified additional CpG sites for future investigation.